TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 29797519
Drug: Prior dose
Normalized name: Priorix
DrugBank: Rubella virus vaccine (DB10317)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prior dose adjustment groups
Study: 10475721
Drug: Olanzapine (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olanzapine (3 mg)
Study: 9084525
Drug: Epidural morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural morphine 3 mg + 10 ml 2% lidocaine before general anesthesia (group II)
Study: 9084525
Drug: Epidural morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural morphine 3 mg + 3 ml 2% lidocaine before wound closure (group III)
Study: 9084525
Drug: Non-steroid analgesics
Normalized name: NON-STEROIDAL ANTI-INFLAMMATORY ANALGESICS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-steroid analgesics (diclofenac sodium 50 mg, iv, q4h) (group I)
Study: 2017271
Drug: Intravenous L-carnitine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous L-carnitine therapy (2 g i.v. 3 times weekly for 6 months)
Study: 2017271
Drug: Intravenous L-carnitine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous L-carnitine therapy (1 g i.v. for 10 months after initial treatment)
Study: 2017271
Drug: Placebo (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (2 g i.v. 3 times weekly for 6 months)
Study: 2017271
Drug: Intravenous L-carnitine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous L-carnitine therapy
Study: 6218109
Drug: Intramuscular administration
Normalized name: Japanese Encephalitis vaccine for intramuscular administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular administration of mezlocillin (1 g every eight hours)
Study: 6218109
Drug: Intravenous administration
Normalized name: intravenous administration set
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous administration of mezlocillin (2 g every eight hours)
Study: 6218109
Drug: Both routes
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both routes of administration (i.m. and i.v.)
Study: 6218109
Drug: Intramuscular administration
Normalized name: Japanese Encephalitis vaccine for intramuscular administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular administration of mezlocillin
Study: 26137956
Drug: AZD3241 600
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZD3241 600 mg orally twice a day for 8 weeks
Study: 22292526
Drug: i.v. alteplase
Approvals — FDA: no, EMA: no, PMDA: no
Description: i.v. alteplase (rt-PA) at a dosage of 0.9 mg/kg of body weight
Study: 22292526
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment according to national guidelines
Study: 17584058
Drug: Tumor necrosis
Normalized name: Tumor necrosis factor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tumor necrosis factor-alpha monoclonal antibodies
Study: 15020186
Drug: SMS reminders
Normalized name: Samarium Sm-153
DrugBank: Samarium Sm-153 (DB12905)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SMS reminders for vaccination doses
Study: 10479167
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy with low-dose IFN-alpha
Study: 1820675
Drug: Tenoxicam (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tenoxicam (20 mg intramuscular)
Study: 6293073
Drug: Hormonal therapy
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hormonal therapy with tamoxifen and drostanolone propionate (n = 34)
Study: 6293073
Drug: Chemotherapy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy with the CMF protocol (n = 30)
Study: 6293073
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of hormonal therapy and chemotherapy (n = 34)
Study: 31587960
Drug: Bruder Compress
Normalized name: Ulva compressa extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bruder Compress twice a day
Study: 31587960
Drug: Warm washcloth
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warm washcloth used for ten minutes twice a day without reheating
Study: 31587960
Drug: Bruder Compress
Normalized name: Ulva compressa extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bruder Compress twice daily vs once daily
Study: 21343342
Drug: A0001 (α-tocopherylquinone)
Normalized name: Tocopherylquinone
DrugBank: Tocopherylquinone (DB14094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: A0001 (α-tocopherylquinone) at doses of 0.25 g and 0.5 g under fasted state; 0.5 g to 6 g with high-fat meal
Study: 21343342
Drug: A0001 (α-tocopherylquinone)
Normalized name: Tocopherylquinone
DrugBank: Tocopherylquinone (DB14094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: A0001 (α-tocopherylquinone) administered in divided doses (0.735 g, 3 times per day)
Study: 17378175
Drug: Monoclonal antibody
Normalized name: Monoclonal antibody
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monoclonal antibody A33 in Phase I trial
Study: 17378175
Drug: Combination chemotherapies
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination chemotherapies in Phase II trial
Study: 17378175
Drug: New therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: New therapy using newly developed material in Phase III trial
Study: 17378175
Drug: Antihypertension agents
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antihypertension agents in Phase III trial
Study: 11867968
Drug: minocycline 100/50
Approvals — FDA: no, EMA: no, PMDA: no
Description: minocycline 100/50 mg
Study: 11867968
Drug: lymecycline 300
Normalized name: lymecycline 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: lymecycline 300 mg
Study: 11867968
Drug: minocycline 50
Normalized name: minocycline 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: minocycline 50 mg
Study: 9865617
Drug: Acetazolamide (AZM)
Normalized name: Acetazolamide
DrugBank: Acetazolamide (DB00819)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acetazolamide (AZM) 500 mg/day for 2 weeks
Study: 24523666
Drug: Lower intensity
Normalized name: flowers
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lower intensity renal replacement therapy (RRT)
Study: 24523666
Drug: Higher intensity
Normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Higher intensity renal replacement therapy (RRT)
Study: 19723080
Drug: Grape Juice
Normalized name: grape juice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Grape Juice (5.5 mL/kg daily for 8 weeks)
Study: 16951956
Drug: Radiosynoviorthesis (RSO)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiosynoviorthesis (RSO) with intra‐articular radionuclide plus glucocorticoid (GC) injection
Study: 16951956
Drug: Placebo plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo plus glucocorticoid (GC) injection
Study: 11559545
Drug: ICI 182,780
Approvals — FDA: no, EMA: no, PMDA: no
Description: ICI 182,780 50 mg
Study: 11559545
Drug: ICI 182,780
Approvals — FDA: no, EMA: no, PMDA: no
Description: ICI 182,780 125 mg
Study: 11559545
Drug: ICI 182,780
Approvals — FDA: no, EMA: no, PMDA: no
Description: ICI 182,780 250 mg
Study: 9786257
Drug: Conventional long-term
Normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conventional long-term anticoagulation (LTA) therapy: initial intravenous standard heparin followed by warfarin on days 3 to 5, continued for 3 months.
Study: 9786257
Drug: Short-term anticoagulation
Normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Short-term anticoagulation therapy: same heparin therapy followed by warfarin on days 2 to 3, continued for 6 weeks.
Study: 9786257
Drug: Short-term anticoagulation
Normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Short-term anticoagulation therapy
Study: 9786257
Drug: Conventional long-term
Normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conventional long-term anticoagulation (LTA) therapy
Study: 8152348
Drug: n-3 polyunsaturated
Normalized name: Omega-3 (n-3) polyunsaturated fatty acids
Approvals — FDA: no, EMA: no, PMDA: no
Description: n-3 polyunsaturated fatty acids (PUFA) 20 g
Study: 8152348
Drug: n-6 PUFA
Normalized name: 18:3 (n-6)
Approvals — FDA: no, EMA: no, PMDA: no
Description: n-6 PUFA 20 g
Study: 2463524
Drug: Pacemaker implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pacemaker implant (VVI or DDD)
Study: 1711873
Drug: Low-dose prednisolone
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose prednisolone
Study: 28836493
Drug: Usual care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual care plus an enhanced rehabilitation package (patient-held information workbook, goal-setting diary, six additional therapy sessions)
Study: 24165282
Drug: Intrathecal baclofen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrathecal baclofen treatment for three months
Study: 24165282
Drug: Placebo treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo treatment for three months
Study: 24165282
Drug: Intrathecal baclofen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrathecal baclofen treatment
Study: 18210310
Drug: Anesthetic cream
Normalized name: DIBUCAINE/DIPERODON ANESTHETIC CREAM
DrugBank: Benzocaine (DB01086)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Anesthetic cream (lidocaine/prilocaine) applied prior to galactography in Group B (27 patients)
Study: 18210310
Drug: No anesthetic
Normalized name: Gelato Anesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: No anesthetic cream in Group A (19 patients)
Study: 8660042
Drug: D-penicillamine treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: D-penicillamine treatment
Study: 1819153
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg frusemide
Study: 6345111
Drug: Liquid antacid
Normalized name: GNP Liquid Antacid Maximum Strength 400mg-400mg-40mg/5ml Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liquid antacid (Maalox Therapeutic Concentration, 15 ml, 80 mEq, taken 7 times daily)
Study: 6345111
Drug: Placebo (taken
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (taken 7 times daily)
Study: 30126028
Drug: High-dose peanut
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose peanut OIT (3000 mg)
Study: 30126028
Drug: Low-dose peanut
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose peanut OIT (300 mg)
Study: 29098683
Drug: Sufentanil (target‐controlled
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sufentanil (target‐controlled infusion, effect‐site concentration of 0.3 ng.ml‐1)
Study: 9733365
Drug: Moxonidine (0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moxonidine (0.4 mg/day; 1 month)
Study: 29726939
Drug: Ustekinumab 130
Normalized name: ustekinumab 130 MG in 26 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ustekinumab 130 mg
Study: 29726939
Drug: Ustekinumab (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ustekinumab (all doses)
Study: 19725852
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of MR presence and viability in the region of the pacing lead
Study: 18727339
Drug: Warm compresses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warm compresses applied to the injection site before self-injection
Study: 18727339
Drug: Usual methods
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual methods of injection preparation
Study: 21623649
Drug: Vitamin B12
Normalized name: Vitamin B12
DrugBank: Cyanocobalamin Co-57 (DB09385)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin B12 injections
Study: 6299982
Drug: 0.5 mg
Normalized name: biotin 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg terbutaline subcutaneously
Study: 6299982
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg terbutaline orally
Study: 31864383
Drug: Generic G-CBT
Normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Generic G-CBT program for anxiety disorders
Study: 23754205
Drug: Metronidazole gel
Normalized name: Metronidazole
DrugBank: Metronidazole (DB00916)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Metronidazole gel (3% w/v)
Study: 23754205
Drug: Metronidazole solution
Normalized name: Metronidazole
DrugBank: Metronidazole (DB00916)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Metronidazole solution (0.5% w/v)
Study: 22226343
Drug: Inhaled loxapine
Normalized name: loxapine Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled loxapine 5 mg (bipolar disorder)
Study: 22226343
Drug: Inhaled loxapine
Normalized name: loxapine Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled loxapine 10 mg (bipolar disorder)
Study: 12405366
Drug: Intrathecal drug
Normalized name: beractant
DrugBank: Beractant (DB06761)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intrathecal drug therapy (IDT)
Study: 12405366
Drug: Conventional pain
Normalized name: Dermoplast Pain
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional pain therapy (CPT)
Study: 7840079
Drug: Biotin supplementation
Normalized name: Biotin
DrugBank: Biotin (DB00121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Biotin supplementation (10 mg/d)
Study: 29996800
Drug: Mycophenolate mofetil
Normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Mycophenolate mofetil (MMF) 1.5 g daily in two divided doses
Study: 29996800
Drug: Cyclophosphamide (CYC)
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cyclophosphamide (CYC) given intravenously as a monthly pulse
Study: 20442386
Drug: Azithromycin (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azithromycin (250 mg for weight 18-35.9 kg or 500 mg for weight >= 36 kg) 3 days per week for 168 days
Study: 19406291
Drug: Sertraline (daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sertraline (daily oral doses starting at 25mg, increasing to therapeutic levels up to 200mg)
Study: 19406291
Drug: Sertraline and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sertraline and Placebo (both groups)
Study: 16586190
Drug: Gabapentin (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gabapentin (300 mg to 3,600 mg)
Study: 11311964
Drug: Gliclazide (80-240
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gliclazide (80-240 mg)
Study: 11311964
Drug: Glibenclamide (5-15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glibenclamide (5-15 mg)
Study: 8985076
Drug: Combined regional/general
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined regional/general anesthesia with intraoperative epidural catheter anesthesia using Bupivacaine and postoperative epidural morphine
Study: 8985076
Drug: General anesthesia
Normalized name: Ethers for general anesthesia
Approvals — FDA: no, EMA: no, PMDA: no
Description: General anesthesia with postoperative patient-controlled intravenous morphine
Study: 8501777
Drug: Orange juice
Normalized name: Orange juice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orange juice (1.2 l. per day, containing 60 mEq. potassium and 190 mEq. citrate)
Study: 3630312
Drug: sublingual nifedipine
Normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: sublingual nifedipine 20 mg
Study: 3630312
Drug: intravenous nifedipine
Normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: intravenous nifedipine 1 mg
Study: 27233239
Drug: Vernakalant (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vernakalant (3 mg/kg infusion over 10 min, followed by 2 mg/kg if AF not terminated)
Study: 25280032
Drug: Pidotimod treatment
Normalized name: pidotimod
DrugBank: Pidotimod (DB11364)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pidotimod treatment for 30 days
Study: 17369518
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group receiving task-specific therapy alone
Study: 9988543
Drug: Estrogen receptor
Normalized name: Estrogen receptor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estrogen receptor status positive
Study: 9988543
Drug: Progesterone receptor
Normalized name: Progesterone receptor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Progesterone receptor status positive
Study: 7859244
Drug: Quinapril (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quinapril (10 mg QD to 20 mg QD, titrated based on blood pressure response)
Study: 7859244
Drug: Quinapril (part
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quinapril (part of antihypertensive regimen)
Study: 28879792
Drug: Naproxen (750
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naproxen (750 mg)
Study: 22088520
Drug: Tirofiban with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tirofiban with unfractionated heparin (UFH)
Study: 18157558
Drug: 10% Isomalt
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10% Isomalt solutions rinsed for 5 minutes daily
Study: 18157558
Drug: 10% Isomalt
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10% Isomalt additions to re- or demineralizing solutions
Study: 18157558
Drug: 10% Isomalt
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10% Isomalt containing toothpaste brushed three times daily
Study: 12588772
Drug: Rosiglitazone 4
Normalized name: rosiglitazone 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosiglitazone 4 mg (twice daily)
Study: 8720318
Drug: Erythromycin (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythromycin (500 mg t.i.d. over 5 days)
Study: 8720318
Drug: Azithromycin (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azithromycin (500 mg o.d. over 3 days)
Study: 1770275
Drug: Gonadotropin releasing
Normalized name: Gonadotropin releasing factor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gonadotropin releasing hormone agonist (GNRHa), Buserelin, prior to and during induction of ovulation by hMG (Group I‐‐long protocol)
Study: 16189630
Drug: Kremezin (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Kremezin (oral carbonaceous adsorbent) paired with conventional treatment (antihypertensive therapy and low-protein diet)
Study: 16189630
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment (antihypertensive therapy and low-protein diet) alone
Study: 12202465
Drug: Alendronate (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alendronate (5 mg or more)
Study: 12202465
Drug: Alendronate (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alendronate (10 mg or more)
Study: 12202465
Drug: Alendronate (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alendronate (5 mg or greater)
Study: 9036798
Drug: Low-dose cidofovir
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose cidofovir (5 mg/kg once weekly for 2 weeks, then 3 mg/kg once every 2 weeks)
Study: 9036798
Drug: High-dose cidofovir
Normalized name: Cidofovir
DrugBank: Cidofovir (DB00369)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: High-dose cidofovir (5 mg/kg once weekly for 2 weeks, then 5 mg/kg once every 2 weeks)
Study: 9036798
Drug: Deferral group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deferral group (treatment deferred until retinitis progressed)
Study: 9036798
Drug: Low-dose cidofovir
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose cidofovir group
Study: 9036798
Drug: High-dose cidofovir
Normalized name: Cidofovir
DrugBank: Cidofovir (DB00369)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: High-dose cidofovir group
Study: 27558098
Drug: Ponesimod regimen
Normalized name: ponesimod
DrugBank: Ponesimod (DB12016)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Ponesimod regimen A (incremental dose increase from 2 to 20 mg in 9 steps)
Study: 27558098
Drug: Ponesimod regimen
Normalized name: ponesimod
DrugBank: Ponesimod (DB12016)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Ponesimod regimen B (10 mg for 7 days followed by a single-dose administration of 20 mg)
Study: 17124721
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg DiaPep277
Study: 17124721
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg mannitol (placebo)
Study: 14727273
Drug: 1.5 mL
Normalized name: Humulin 70/30 1.5 ML Pen
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5 mL hyperbaric bupivacaine 0.5% (7.5 mg)
Study: 14727273
Drug: 4.2 mL
Normalized name: ISOPROPYL ALCOHOL 4.2 mL TOPICAL CLOTH [ISOPROPYL ALCOHOL WIPES]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4.2 mL hypobaric bupivacaine 0.18% (7.5 mg)
Study: 11771827
Drug: Insulin, glucose,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin, glucose, and potassium (GIK) infusion using an euglycemic clamp technique.
Study: 11771827
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no GIK infusion).
Study: 9316182
Drug: ACTH 4‐10
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACTH 4‐10 (1.25 mg intravenously, 30 minutes before testing)
Study: 2961815
Drug: HBIg (0.06
Approvals — FDA: no, EMA: no, PMDA: no
Description: HBIg (0.06 ml/kg) administered intramuscularly within 3 days after exposure, followed by a second dose 1 month later.
Study: 2961815
Drug: HBIg (0.06
Approvals — FDA: no, EMA: no, PMDA: no
Description: HBIg (0.06 ml/kg) administered within 3 days followed by HB vaccine (HEVAC‐B Pasteur 10 micrograms) within 7 days after exposure.
Study: 2681882
Drug: L 841
Normalized name: WITCH HAZEL 841 mg in 1 mL TOPICAL LIQUID [Witch Hazel]
Approvals — FDA: no, EMA: no, PMDA: no
Description: L 841 A (vincristine + prednisone for remission induction, 18 Gy cranial irradiation + intrathecal methotrexate for CNS leukemia prophylaxis, maintenance with MTX iv alternating 5-day course of VCR + PDN + 6-mercaptopurine)
Study: 2681882
Drug: L 841
Normalized name: WITCH HAZEL 841 mg in 1 mL TOPICAL LIQUID [Witch Hazel]
Approvals — FDA: no, EMA: no, PMDA: no
Description: L 841 B (asparaginase added)
Study: 2681882
Drug: I 841
Normalized name: I 123
DrugBank: Iodide I-123 (DB09420)
Approvals — FDA: no, EMA: no, PMDA: no
Description: I 841 C (asparaginase, Adriamycin, high-dose MTX 100 mg/kg)
Study: 24229823
Drug: Montelukast 4
Normalized name: montelukast 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Montelukast 4 to 5 mg once daily
Study: 19826135
Drug: Elesclomol 213
Normalized name: Élesclomol
DrugBank: Elesclomol (DB05719)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Elesclomol 213 mg/m² plus paclitaxel 80 mg/m² (E + P)
Study: 19826135
Drug: Paclitaxel 80
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel 80 mg/m² alone
Study: 16731214
Drug: Nortriptyline, fluoxetine,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nortriptyline, fluoxetine, or placebo (double-blind methodology)